SLN News and Press, Silence Therapeutics Plc

2024-07-09 15:00:45 ET More on BioMarin Pharmaceutical, Legend Biotech, etc. Silence Therapeutics: PV Data For Consideration After ASCVD Treatment Results BioMarin: Short-Term Headwinds But Long-Term Opportunities Remain Legend Biotech's Carvykti Faces Stiff Challeng...

2024-06-28 10:00:07 ET Keay Nakae from Chardan Capital issued a price target of $55.00 for SLN on 2024-06-28 08:03:00. The adjusted price target was set to $55.00. At the time of the announcement, SLN was trading at $19. The overall price target consensus is at $48.33 wi...

2024-06-28 09:00:06 ET Michael Ulz from Morgan Stanley issued a price target of $49.00 for SLN on 2024-06-28 07:44:00. The adjusted price target was set to $49.00. At the time of the announcement, SLN was trading at $19. The overall price target consensus is at $38.00 wi...

2024-06-27 14:33:58 ET More on Silence Therapeutics Silence Therapeutics: PV Data For Consideration After ASCVD Treatment Results Silence Therapeutics achieves $2M research milestone payment from Hansoh Pharma Silence Therapeutics achieves $2M research milestone paym...

Divesiran eliminated the need for phlebotomy in all well-controlled patients following infrequent dosing and was well tolerated Data support advancing divesiran into Phase 2 Company to host conference call today at 8:30am Eastern Time Silence Therapeutics plc (“Si...

2024-06-24 16:06:00 ET Stock Traders Daily has produced this trading report using a proprietary method.  This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...

2024-06-24 09:22:45 ET More on Silence Therapeutics Silence Therapeutics: PV Data For Consideration After ASCVD Treatment Results Silence Therapeutics achieves $2M research milestone payment from Hansoh collaboration Silence releases promising phase 2 results of zerl...

2024-06-24 08:54:57 ET More on Silence Therapeutics Silence Therapeutics: PV Data For Consideration After ASCVD Treatment Results Silence releases promising phase 2 results of zerlasiran to lower lipoprotein Silence Therapeutics reports Q1 results Seeking Alp...

2024-06-21 14:31:06 ET Summary Silence Therapeutics plc results from the phase 1 SANRECO study, using divesiran for the treatment of patients with polycythemia vera, expected end of June 2024. The 7 major polycythemia vera markets are expected to reach $68.5 billion by 2034. P...

2024-06-20 15:30:05 ET Morgan Stanley analyst issues BUY recommendation for SLN on June 20, 2024 12:00PM ET. The previous analyst recommendation was Buy. SLN was trading at $18.9 at issue of the analyst recommendation. The overall analyst consensus : BUY. Current ana...